EXICURE, INC.
About EXICURE, INC.
Exicure Inc is a clinical-stage biotechnology company focused on developing treatments for blood-related diseases, with an emphasis on small-molecule therapies that have the potential to benefit a broad range of patients. The company acquired GPCR Therapeutics USA and secured a license for GPC-100 (Burixafor), a clinical-stage small-molecule compound that inhibits the chemokine receptor CXCR4. GPC-100 has demonstrated the ability to effectively mobilize various cell types, including hematopoietic stem cells and lymphocytes, highlighting its broad therapeutic potential across multiple indications.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $0
- Net income
- -$4.9M
- Total assets
- $14.0M
- Market cap
- $18.6M
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $0
- Operating expenses
- $4.2M
- Operating income
- -$4.2M
- Income tax
- -$634.0K
- Net income
- -$4.9M
- EPS (basic)
- $-0.79
- EPS (diluted)
- $-0.79
Balance sheet
- Total assets
- $14.0M
- Current assets
- $4.6M
- Total liabilities
- $10.1M
- Current liabilities
- $3.9M
- Shareholders’ equity
- $3.9M
Cash flow
- Operating cash flow
- -$8.6M
- Investing cash flow
- -$1.8M
- Financing cash flow
- $1.6M
- Net cash flow
- -$8.8M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $18.6M
- EPS (diluted)
- $-0.79
- Shares outstanding
- 6.2M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- May 9, 2018
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $4.9M in FY2025.
- Trading 75% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review EXICURE, INC..
Write a review
News about EXICURE, INC.
News & sentiment via Polygon.io
